{
    "clinical_study": {
        "@rank": "77329", 
        "acronym": "C012013", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "BID"
            }, 
            {
                "arm_group_label": "MRX-6", 
                "arm_group_type": "Experimental", 
                "description": "BID"
            }
        ], 
        "brief_summary": {
            "textblock": "Randomized, double-blind, parallel group, placebo-controlled, multicenter, efficacy and\n      safety study in subjects with mild to moderate atopic dermatitis.\n\n      Following the double blind period, subjects will be allowed to continue treatment with\n      topical MRX-6 Cream 2% in an open-label extension.  Demonstrate the efficacy of MRX-6 Cream\n      2% compared to Vehicle for the treatment of the signs and symptoms of atopic dermatitis and\n      demonstrate the safety of MRX-6 Cream 2% for the treatment of the signs and symptoms of\n      atopic dermatitis."
        }, 
        "brief_title": "Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MRX-6 Cream 2%", 
        "condition": "Atopic Dermatitis", 
        "condition_browse": {
            "mesh_term": [
                "Dermatitis", 
                "Dermatitis, Atopic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects, \u22652 years of age and \u226417 years of age, of any race or ethnicity\n\n          -  Must have clinical diagnosis of mild to moderate atopic dermatitis (AD) at both\n             Screening and Baseline Visits, defined as IGA score of 2 or 3 (Hanifin and Rajka,\n             Rothe 1980)\n\n          -  Must have AD affecting \u2265 5% total body surface area (TBSA) at Baseline\n\n          -  History of AD for at least 3 months prior to Baseline\n\n          -  Informed consent/assent in accordance with the International Conference on\n             Harmonization (ICH) Good Clinical Practice (GCP) Guideline (40 CFR 63.1335) and\n             applicable regulations, before completing any study-related procedures\n\n        Exclusion Criteria:\n\n          -  Use of topical corticosteroids within 7 days prior to Baseline\n\n          -  Use of systemic corticosteroids, topical calcineurin inhibitors, photo-therapy (eg,\n             PUVA, UVB) or immunosuppressive therapy (eg, cyclosporine) within 14 days prior to\n             Baseline\n\n          -  Subjects that require systemic therapy for the treatment of atopic dermatitis\n\n          -  Use of systemic anti-infective or antibiotic treatment within 14 days prior to\n             Baseline\n\n          -  Subjects who present with clinical conditions other than AD that may interfere with\n             the evaluation (eg, generalized erythroderma, acne, Netherton's Syndrome, psoriasis)\n\n          -  Secondary infection of AD (bacterial, viral or fungal) within the skin area under\n             study or open skin infections in any area at Baseline\n\n          -  Women of childbearing potential who are lactating or pregnant as determined by urine\n             pregnancy test at Screening.  \u2022 History of MRX-6 cream 2% sensitivity or to any\n             component of the test article\n\n          -  History of severe anxiety and/or depression; any history of suicide attempt\n\n          -  Subjects with a history of human immunodeficiency virus (HIV) as determined by\n             medical history\n\n          -  Subjects with any screening clinical laboratory result outside the normal range that\n             is clinically relevant in the opinion of an appropriately qualified physician\n\n          -  Subjects who, in the opinion of the Investigator, would be non compliant with the\n             visit schedule or study procedures\n\n          -  Participation in any other investigational trial within 6 weeks of Baseline, or\n             during study conduct\n\n          -  Chronic condition(s) which are either unstable or not adequately controlled\n\n          -  Use of non-sedating anti-histamines within 7 days of first dose or at any time during\n             study conduct\n\n          -  Drug or alcohol abuse, mental dysfunction, or other condition limiting the subject's\n             ability to be compliant with study-related procedures"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "2 Years"
        }, 
        "firstreceived_date": "January 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02031445", 
            "org_study_id": "C012013"
        }, 
        "intervention": {
            "arm_group_label": "MRX-6", 
            "intervention_name": "MRX-6", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 7, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tel Aviv", 
                    "country": "Israel", 
                    "zip": "64239"
                }, 
                "name": "Tel Aviv Sourasky Medical Center address"
            }, 
            "investigator": {
                "last_name": "Eli Sprecher, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "official_title": "A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MRX-6 Cream 2% in Pediatric Subjects With Mild to Moderate Atopic Dermatitis Followed by an Open Label Extension", 
        "overall_contact": {
            "email": "pj@celsustx.com", 
            "last_name": "Pablo Jimenez, MD", 
            "phone": "646-350-0702"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Investigator's Global Assessment", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02031445"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Adverse Events", 
            "measure": "Safety", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "source": "Celsus Therapeutics PLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Celsus Therapeutics PLC", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "N/A", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}